- In the
management of Parkinson's disease, due to the
chronic nature of Parkinson's
disease (PD), a broad-based
program is
needed that
includes patient...
- Long-term
physiotherapy (greater than six months)
reduces the need for
antiparkinsonian medication;
multidisciplinary rehabilitation programs combined with...
-
Hypokinesia and rigidity,
especially in
juvenile cases, can be
treated with
antiparkinsonian drugs, and
myoclonic hyperkinesia can be
treated with
valproic acid...
-
Piribedil is an
antiparkinsonian agent and
piperazine derivative which acts as a D2 and D3
receptor agonist. It also has α2-adrenergic
antagonist properties...
-
Central Nervous System Sedative-Hypnotics, Alcohols,
Antiepileptics and
Antiparkinsonian Drugs". www.jaypeedigital.com.
Retrieved 22
December 2021. Skibiski...
- (R)-1-aminoindan, is
pharmacologically active and is an
active metabolite of the
antiparkinsonian agent rasagiline.
Through its (R)-enantiomer (R)-1-aminoindane, 1-aminoindane...
- that memantine,
along with amantadine, has been
widely used as an
antiparkinsonian agent since at
least 1994.
Although amantadine and
memantine have fairly...
- for
prophylaxis against the
influenza virus A in 1966. In 1968, its
antiparkinsonian effects were
serendipitously discovered. In 1973, the Food and Drug...
-
Pardoprunox (INN; code name SLV-308) is an
antiparkinsonian drug
developed by
Solvay for the
treatment of Parkinson's
disease that
reached phase III clinical...
- is an
antihistamine and
anticholinergic used as an
antipruritic and
antiparkinsonian agent. It is an
analog of diphenhydramine.
Bazex A,
Dupre A, Christol...
